Protein / target
B-cell antigen receptor complex-associated protein beta chain
Protein at a glance
Biological role
Transmembrane signaling receptor activity
Primary system
Immune system
Strongest disease association
agammaglobulinemia
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
1 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation
Subcellular location
Domains and Gene Ontology detail (14)Hide
Domains & features
Gene Ontology
- CB cell receptor complex
- Cexternal side of plasma membrane
- Cextracellular exosome
- CIgM B cell receptor complex
- Cplasma membrane
- Fidentical protein binding
- Ftransmembrane signaling receptor activity
- Padaptive immune response
- PB cell differentiation
- PB cell receptor signaling pathway
- Pimmune response
- Psignal transduction
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·Required in cooperation with CD79A for initiation of the signal transduction cascade act…
- ·B cell receptor complex
- ·IgM B cell receptor complex
- ·adaptive immune response
Kinase signalling
- ·Required in cooperation with CD79A for initiation of the signal transduction cascade act…
View underlying pathways (4)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
B-cell antigen receptor complex-associated protein beta chain binding agent
Appears in clinical studies involving diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, B-cell non-Hodgkin lymphoma, neoplasm
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 308 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 1 total
diffuse large B-cell lymphoma · diffuse large B-cell lymphoma · B-cell non-Hodgkin lymphoma
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Trial status changed
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- New publicationPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
- Regulatory approval
Approval: Polivy (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.